Acquisition PotentialMLTX has long been viewed as an acquisition target, which suggests potential future growth and value creation for investors.
Market OpportunityThe HS market is expected to be large enough for multiple efficacious therapies to achieve commercial success, providing a significant commercial opportunity for MLTX.
Product DifferentiationSLK's nanobody size should allow for better local distribution at lesion sites and dual targeting of IL-17A/F should be superior to IL-17A inhibition alone.